$CAPR: The FDA's Advisers Voted 9-3 Against Capricor's Duchenne Therapy. The Agency Kept Reviewing Anyway. 53 Days to the Answer
Capricor lost 80% of its value in five sessions after a 9-3 advisory vote against deramiocel. Then the FDA accepted a refined upper-limb indication and set a November 22 decision date. The trial math, the $4 cash floor, the $180 million voucher nobody prices, and the scenario zones.
In late July, a panel of the FDA's outside advisers looked at Capricor Therapeutics (Nasdaq: CAPR) and its cell therapy for Duchenne muscular dystrophy and voted 9-3 that the pivotal trial did not provide substantial evidence of effectiveness. The stock, which had closed at $19.70 the Friday before the review documents dropped, finished that week at $3.85. Roughly 80% of the company's market value was gone in five trading sessions.
Two months later, Capricor closed Tuesday at $8.57, more than double the low, and is trading near $9.80 Wednesday morning. The FDA is still reviewing the application. The agency accepted a major amendment to the filing, moved the decision date to November 22, and let the company refine the indication it is asking for. This week the stock is back on the trending list because the World Muscle Society congress opened in Hiroshima on Tuesday, where Capricor is presenting the 24-month dataset it built that amendment on, with the oral presentation scheduled for October 3.
So the setup is unusual and worth stating plainly: a drug that a federal advisory committee rejected 9-3 is 53 days from an approval decision, and the market has already priced back in a meaningful chance the agency says yes anyway.
How Capricor Got Here
Deramiocel, also called CAP-1002, is an allogeneic cell therapy derived from donor heart tissue, aimed at Duchenne muscular dystrophy, the fatal genetic muscle-wasting disease that affects boys almost exclusively. Most DMD patients die of cardiac or respiratory failure; deramiocel was originally positioned at the cardiomyopathy that kills them.
The regulatory history reads like a case study in whiplash. In July 2025 the FDA issued a Complete Response Letter, saying the application lacked substantial evidence of effectiveness, a rejection that arrived after the agency's then-biologics chief canceled a scheduled advisory committee meeting, according to reporting by STAT News. Capricor publicly disputed the agency's reading of its data. Then in March 2026 the FDA lifted the CRL and resumed the review as a Class 2 resubmission with an August 22 decision date. Then the agency scheduled the advisory committee meeting after all. On July 27, 2026, the FDA's briefing documents hit and the stock fell from $19.70 to $7.00. On July 29 the Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against, and the stock bottomed at $3.85 on July 31.
What happened next is the part the stream mostly hasn't digested. In August, Capricor submitted 24-month open-label extension data from its Phase 3 HOPE-3 study plus additional statistical analyses, and refined the proposed indication to focus on upper limb function rather than cardiomyopathy. Upper limb function was HOPE-3's primary endpoint, and the trial hit it. The FDA classified the submission as a major amendment, extended the decision date by three months to November 22, and cited the significant unmet medical need in DMD when it did. An agency that wanted a quick, clean second rejection had a much easier path available. It did not take it.
There is also a shareholder lawsuit running in the background, and a fight with the company's own US distribution partner that most coverage skips entirely. Both matter for what the stock is worth in the scenarios that follow.
Get the next briefing free in your inbox before the market prices it in: Join AlphaBriefing
At Tuesday's $8.57 close, the market was paying roughly $500 million for a company holding about $4 per share in cash, a drug with a 9-3 adcomm vote against it, a met primary endpoint the label request now leans on, and a decision date 53 days out. Whether that price is generous or cheap depends entirely on how you weight three doors: approval, a second rejection, and the messy middle. The trial math, the cash clock, the voucher nobody is pricing, and the zone-by-zone breakdown is below.
The rest of this briefing is for paid members: what the HOPE-3 numbers actually show and the data revision the lawsuit is built on, the real cash-per-share floor and burn math, the partner dispute that clouds the US economics even in the approval case, the $150-195 million voucher the market is ignoring, and the scenario-by-scenario price zones into November 22.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish, the analysis private intel clients pay four figures for, at a fraction of that.